The outlook of companies tied to Sildenafil's past presents a intricate investment scenario . While the initial boom generated substantial returns , generic alternatives have significantly diminished sales . Investing in associated pharmaceutical businesses now requires a careful assessment of proprietary rights , evolving medical changes, and the